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Abstract
Background:  We previously described the selection of a T20-dependent human
immunodeficiency virus type-1 (HIV-1) variant in a patient on T20 therapy. The fusion inhibitor T20
targets the viral envelope (Env) protein by blocking a conformational switch that is critical for viral
entry into the host cell. T20-dependent viral entry is the result of 2 mutations in Env (GIA-SKY),
creating a protein that undergoes a premature conformational switch, and the presence of T20
prevents this premature switch and rescues viral entry. In the present study, we performed 6
independent evolution experiments with the T20-dependent HIV-1 variant in the absence of T20,
with the aim to identify second site compensatory changes, which may provide new mechanistic
insights into Env function and the T20-dependence mechanism.
Results: Escape variants with improved replication capacity appeared within 42 days in 5 evolution
cultures. Strikingly, 3 cultures revealed the same single amino acid change in the CD4 binding region
of Env (glycine at position 431 substituted for arginine: G431R). This mutation was sufficient to
abolish the T20-dependence phenotype and restore viral replication in the absence of T20. The
GIA-SKY-G431R escape variant produces an Env protein that exhibits reduced syncytia formation
and reduced cell-cell fusion activity. The escape variant was more sensitive to an antibody acting
on an early gp41 intermediate, suggesting that the G431R mutation helps preserve a pre-fusion Env
conformation, similar to T20 action. The escape variant was also less sensitive to soluble CD4,
suggesting a reduced CD4 receptor affinity.
Conclusion:  The forced evolution experiments indicate that the premature conformational
switch of the T20-dependent HIV-1 Env variant (GIA-SKY) can be corrected by a second site
mutation in Env (GIA-SKY-G431R) that affects the interaction with the CD4 receptor.
Background
Host cell entry of Human Immunodeficiency Virus type-1
(HIV-1) is a critical step in the virus life cycle, which
requires the recognition of the host cell receptor CD4 and
a co-receptor, CCR5 or CXCR4, by the viral envelope
(Env) glycoprotein. Env is arranged on the virus particle as
trimeric spikes, comprising three gp120 and three gp41
molecules, anchored within the viral membrane via the
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gp41 transmembrane (TM) domain. Binding of the sur-
face subunit gp120 to CD4 and a co-receptor on the T-cell
surface triggers conformational changes in the Env com-
plex, leading to the insertion of the hydrophobic N-termi-
nal fusion peptide (FP) of gp41 into the target cell
membrane (reviewed in [1]). Subsequent changes within
the gp41 ectodomain (gp41e) involve two leucine zipper-
like motifs; heptad repeat 1 (HR1) and heptad repeat 2
(HR2). Ultimately, HR1 and HR2 from three gp41 mole-
cules assemble into a highly stable 6-helix bundle struc-
ture, which juxtaposes the viral and cellular membranes
for the fusion event [2-4]. The change in free energy asso-
ciated with this structural transition within gp41e is pre-
dicted to be sufficient to cause lipid mixing and
membrane fusion [5,6]. Peptide fusion inhibitors that
bind to one of the HR motifs can block this conforma-
tional switch, and thus inhibit viral entry [7-10].
The fusion inhibitor T20 (also called DP-178, Enfuvirtide
and Fuzeon™) is the most clinically advanced drug of a
new class of antivirals designed to inhibit viral entry [11].
T20 is a synthetic 36 amino acid peptide derived from the
C-terminal region of HR2 [8,12]. By competitive binding
to HR1, T20 blocks the formation of the 6-helix bundle,
which is a prerequisite for membrane fusion and viral
entry [8,13]. T20 has also been proposed to have addi-
tional target sites within Env; the C4 region of gp120 and
the viral membrane proximal region of gp41e [14-18].
The C4 region in gp120 is involved in CD4 and co-recep-
tor engagement and differences in how Env engages its
receptors can influence T20 sensitivity [14,15].
HIV-1 variants that are resistant to this compound have
been described and resistance mutations have been iden-
tified within the viral quasispecies of patients on T20 ther-
apy [19-24]. Sequence analysis of the resistant viral
population revealed the acquisition of mutations mainly
within a stretch of three HR1 amino acids, glycine-isoleu-
cine-valine (further referred to as the GIV sequence, HXB2
amino acid positions 547 to 549 of gp160). In addition,
mutations flanking this region (amino acids 550–556 of
HR1) have also been proposed to confer a distinct level of
resistance to T20 [25-27].
Recently, we performed a genetic analysis of the entire
HIV-1 gp41e of the viral population from a patient that
failed on T20 therapy [20]. Sequence analysis revealed the
acquisition of the T20-resistance mutation GIA (GIV to
GIA; mutated amino acid underlined) in HR1. We also
documented a subsequent change in the three amino acid
SNY sequence of the HR2 domain (SNY to SKY). We dem-
onstrated that the HR1–HR2 double mutant (GIA-SKY),
which dominated the viral population after 32 weeks of
therapy, was not only highly resistant to T20, but also crit-
ically dependent on the T20 peptide for its replication. We
proposed a mechanistic model that supports this novel
feature of drug-dependent viral entry. Briefly, resistance to
T20 is caused by the GIA mutation in HR1, which weak-
ens the interaction with both T20 (resistance) and HR2
(gp41 6-helix bundle formation). Reduced HR1-T20
affinity explains the resistance phenotype, but reduced
HR1–HR2 affinity negatively impacts Env-mediated
fusion and HIV-1 fitness [20,28]. The T20-dependence
phenotype is caused by the introduction of the SKY muta-
tion in HR2, which attempts to re-stabilise the HR1–HR2
affinity defect caused by the GIA resistance mutation in
HR1. However, the SKY mutation creates a hyper-
fusogenic Env-gp41 molecule that prematurely undergoes
the conformational switch to a later fusion intermediate
or the 6-helix bundle. T20 is able to prevent this prema-
ture switch by preserving and earlier pre-fusion conforma-
tion, enabling gp41 to undergo the necessary
conformational switch at the correct moment in the
fusion process. In the present study, we performed forced
evolution experiments with the T20-dependent virus in
the absence of the T20 peptide with the aim to identify
second site compensatory changes, which could provide
new mechanistic insights into Env function and the T20-
dependence mechanism.
Results
The T20-dependent virus evolves to T20-independence
We performed forced evolution experiments with the T20-
dependent virus (GIA-SKY) in the absence of the T20 pep-
tide. We previously demonstrated the power of the forced
evolution approach in diverse HIV-1 studies [29-31]. Evo-
lution cultures were started by transfection of the GIA-SKY
molecular clone into the SupT1 T-cell line. Viral replica-
tion was monitored over a 42 day period and virus plus
cell samples were taken at several times in the course of
the experiment. Efficient viral spread was measured via
CA-p24 determination and consequently virus-induced
syncytia were observed in 5 of the 6 evolution cultures.
The replication capacity of these evolved virus samples
was assayed by infection of fresh SupT1 cells with an
equal amount of virus. We included the T20-dependent
starting virus (GIA-SKY) as well as the wild-type virus
(GIV-SNY) as controls (Fig. 1A). Evolution cultures 1, 5
and 6 replicated very efficiently, producing CA-p24 to lev-
els above that of the wild-type and evolution cultures 2
and 4 produced CA-p24 levels similar to the wild-type,
confirming the presence of replication competent viral
populations that no longer require the T20 peptide. Only
evolution culture 3 showed no obvious sign of viral
escape.
Genotypic analysis of the escaped viruses
One may anticipate that the phenotypic reversion would
be caused by back-mutation of the SKY sequence in HR2
to the wild-type SNY sequence, which would remove theRetrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
Page 3 of 11
(page number not for citation purposes)
Evolution of the T20-dependent HIV-1 variant Figure 1
Evolution of the T20-dependent HIV-1 variant. (A) Replication of wild-type (GIV-SNY), T20-dependent (GIA-SKY) and 
HIV-1 variants obtained in evolution cultures in the absence of T20. Bars represent CA-p24 values at day 4 post-infection, 
which represent the relative differences in replication capacity. Infection of fresh SupT1 cells was performed with an equal 
amount of the viral stocks obtained at day 42 of evolution. (B) Summary of observed mutations, replication capacity and syn-
cytia formation of the six evolution cultures after 42 days of evolution. Replication without T20 and syncytia formation repre-
sent relative differences observed in infection experiment displayed in 1A (-, no replication or syncytia; ++++, high replication 
or all cells involved in syncytia). (C) Schematic of mutations in the Env protein. The complete Env gene is shown (not to scale) 
with the location of the original GIA-SKY mutations and the second site changes selected in the evolution cultures. The G431R 
change that was selected in multiple cultures is marked in bold. Both gp160 and gp41 HxB2 numbering references are included.Retrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
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T20-dependence phenotype. This would produce the GIA
single mutant, which is T20-resistant, but no longer
dependent on T20 [20]. Although this may seem the most
likely outcome, second site compensatory changes else-
where in the Env glycoprotein would also be a possibility.
In order to determine the sequence changes in these phe-
notypic revertants, we PCR-amplified the entire Env gene
from cellular proviral DNA and analysed the sequence for
mutational changes (Fig. 1B and 1C). No changes in or
directly adjacent to the GIA motif in HR1 or the SKY motif
in HR2 were detected. Evolution culture 3, which showed
no sign of viral escape, did not reveal any mutational
changes within the entire Env gene. All other cultures that
yielded an escape viral population showed at least one
mutation in the Env gene. Evolution culture 2 showed a
single amino acid change A221V in the C2 region of
gp120. This amino acid is highly conserved in natural sub-
type B isolates [52], indicating that it plays an important
role in Env function. Evolution culture 6 acquired multi-
ple mutations in gp41 but no changes were seen within
gp120. One change was observed in HR1 (Q567R) and 3
partial changes in the cytoplasmic tail (CT), N750N/T,
Y762Y/C and Q799Q/H. Of most interest were evolution
cultures 1, 4 and 5 that all acquired the same point muta-
tion (G431R; all identical codon changes GGA-to-AGA),
with no changes elsewhere in the Env protein. The G431R
mutation is positioned in the C4 region of gp120, which
plays a critical role in CD4 and co-receptor engagement
[32-35]. Amino acid position 431 is highly conserved in
natural subtype B isolates [52], which suggests that it plays
an important role in Env function. It is striking that the
same mutation was selected in 3 independent evolution
cultures, suggesting this mutation may play a key role in
the phenotypic reversion to T20-independence. We there-
fore decided to investigate this revertant (GIA-SKY-
G431R) in more detail.
The G431R mutation rescues the T20-dependent virus
The G431R mutation was introduced into the GIA-SKY
molecular clone and tested for its impact on viral replica-
tion and T20 resistance/dependence. Viral DNA con-
structs were transfected into SupT1 cells and cultured in
the presence or absence of T20 (Fig. 2). Replication of the
GIA-SKY virus was dependent on the T20 peptide as pre-
viously reported [20]. The GIA-SKY-G431R revertant was
able to replicate in the absence of T20, confirming that the
G431R mutation in gp120 is sufficient for the loss of the
T20-dependent phenotype. The GIA-SKY-G431R revertant
is resistant to T20 because it still contains the crucial T20-
resistance mutation GIA.
We next tested the hypothesis that the G431R mutation in
the GIA-SKY-G431R revertant represents a compensatory
mutation that reduces or controls the structural transition
in the GIA-SKY Env protein. We thus propose that the
G431R mutation may offer a similar mechanistic check as
the T20 peptide and preserve a pre-fusion intermediate
necessary for correct gp41 conformational changes. To test
this, we performed a cell-cell fusion assay, which specifi-
cally measures Env fusion activity (Fig. 3). In this assay,
Replication of the T20-dependent GIA-SKY mutant and the GIA-SKY-G431R revertant virus Figure 2
Replication of the T20-dependent GIA-SKY mutant and the GIA-SKY-G431R revertant virus. Molecular clones 
were transfected in SupT1 cells that were cultured with (100 ng/ml) and without T20. Virus replication curves were made over 
a 7-day period. Closed circles represent the original GIA-SKY mutant virus and open circles the GIA-SKY-G431R revertant. 
This is a representative experiment, similar results were observed in 3 repeated experiments including results in figure 4, top.Retrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
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one cell expresses the wild-type or mutant Env protein
and the other cell the appropriate receptors (CD4 and
CXCR4). Fusion was scored by the formation of syncytia.
In addition, we introduced an LTR-luciferase reporter in
the acceptor cell that is activated upon cell fusion by Tat
protein that is expressed in the donor cell. We measured
dramatically reduced fusion activity (syncytia and luci-
ferase counts) for the GIA-SKY-G431R revertant compared
to the GIA-SKY mutant (black bars) (Fig. 3). Addition of
T20 similarly reduces the fusogenicity of the GIA-SKY
mutant (shaded bars), although the effect is more modest
than that of the G431R reversion as we only used 20 ng/
ml of T20. However, we previously demonstrated that T20
has a dose dependent inhibitory effect in this assay, with
higher concentrations significantly blocking cell-cell
fusion [20]. This result is consistent with the idea that
both the exogenous T20 peptide and the endogenous
G431R mutation have a moderating impact on the hyper-
fusogenic GIA-SKY Env mutant. They are both able to con-
trol or down-regulated the hyper-fusogenicity of the GIA-
SKY Env protein, which normally undergoes a premature
conformational switch to the 6-helix bundle structure.
Influence of amino acid 431 on Env function
We decided to investigate the effect of amino acid 431 in
more detail. Because the C4 region has been implicated as
a contact site for host cell CD4 and co-receptor engage-
ment, amino acid changes in this region may affect the
ability of Env to interact with CD4 and/or co-receptor and
thereby influence the cell-cell and virus-cell interactions
[32-36]. The X-ray structure of the HIV-1 Env protein is
consistent with this possibility because amino acid 431 is
located within the critical CD4 binding site [37,38]. Alter-
natively, changes at amino acid 431 may affect the Env-
CD4 interaction in a more indirect manner through an
effect on the folding of this complex glycoprotein.
The T20-independent phenotype is caused by the replace-
ment of a neutral glycine with a positively charged
arginine at position 431. We therefore wanted to test what
effect the introduction of a negatively charged glutamic
acid at this position would have on the GIA-SKY mutant.
We constructed the molecular clone GIA-SKY-G431E and
tested the ability of this mutant to replicate with and with-
out T20. Transfection of this molecular clone into SupT1
cells resulted in a replication defective virus both with and
without T20 (Fig. 4, top). This result demonstrates that
amino acid position 431 is critical for Env function and
that not any substitution at this position will rescue the
GIA-SKY mutant.
We next tested the effect of G431R and G431E on the
wild-type virus (GIV-SNY) (Fig. 4, bottom). As expected,
replication of the wild-type was strongly inhibited by T20.
Introduction of the positive arginine (G431R) resulted in
increased replication of the wild-type in the absence of
T20. This may be due to the severe syncytia-formation
defect that this mutant exhibits in cell culture on SupT1
cells, which allows the cells to survive longer and hence
allows the virus to replicate freely and subsequently pro-
duce higher quantities of CA-p24 (see discussion for
details). Introduction of the negatively charged glutamic
acid (G431E) completely abolished viral replication of
the wild-type, both with and without T20, as observed in
the context of the GIA-SKY virus. However, when an alter-
native neutral amino acid (alanine which is the most anal-
ogous amino acid to the endogenous glycine; G431A) was
introduced into the wild-type virus, replication and syncy-
tia formation was re-established. As expected, all C4
mutants in the context of the wild-type sequence were
totally sensitive to the T20 peptide (Fig. 4, bottom/right).
G431R prevents an early gp41 conformational switch by 
counteracting hyper-fusogenicity
We further analysed the molecular clones in a cell-cell
fusion assay to directly measure their effect on Env func-
tion (Fig. 5). As previously reported, GIA-SKY Env is
hyper-fusogenic; approximately 1.2–1.5 fold more
Cell-cell fusion assay with the GIA-SKY mutant and the GIA- SKY-G431R revertant Figure 3
Cell-cell fusion assay with the GIA-SKY mutant and 
the GIA-SKY-G431R revertant. SupT1 cells were trans-
fected with the HIV-1 pLAI constructs indicated below the 
X-axis. One day later, transfected cells were mixed with 
SupT1 cells containing a Tat-responsive LTR-luciferase 
reporter gene construct with (20 ng/ml) or without T20. 
After 24 hours, formation of syncytia was analysed by light 
microscopy (-, no syncytia; ++++, all cells involved in syncy-
tia) and quantitated by measurement of luciferase activity in 
cell extracts.Retrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
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fusogenic then the wild-type (GIV-SNY) Env and T20 can
control this fusion step by inhibiting the wild-type and
controlling the hyper-fusogenic activity of the GIA-SKY
Env [20]. Indeed, we were able to reproduce this result
and show that 20 ng/ml T20 is sufficient to lower the
fusogenicity of GIA-SKY back to levels of the wild-type
virus. Most importantly, we also measured reduced Env
function for the GIA-SKY-G431R revertant and this inhi-
bition was also observed in the presence of T20. G431R
had the same effect on Env function in the context of wild-
type and this mutant was totally inhibited by T20 as it
does not contain the GIA T20-resistance mutation. Intro-
duction of the negatively charged glutamic acid residue
completely abolished cell-cell fusion activity of the wild-
type virus, consistent with the replication curves of these
mutants in Figure 4. The neutral alanine residue in the
wild-type context showed intermediate fusion activity,
again consistent with the results of replication and syncy-
tia assays shown in Figure 4.
We have shown that GIA-SKY replication in the absence of
T20 is facilitated by the introduction of the G431R muta-
tion in the gp120 C4 region. This finding is consistent
with our model that GIA-SKY is dead due to an overly
aggressive (hyper-fusogenic) Env protein. We propose
that G431R negatively affects the Env/CD4 interaction as
a means to prevent the abortive premature switch of the 6-
helix bundle. To test this, we measured the sensitivity of
the wild-type (GIV-SNY) and revertant (GIA-SKY-G431R)
viruses to the soluble form of CD4 (sCD4), using a stand-
ard virus replication assay to mimic the evolutionary set-
ting (Fig. 6, left panel). sCD4 is able to inhibit virus entry
by competitively binding to the Env-gp120 C4 region of
HIV-1 before the virus engages the cellular CD4 receptor
Replication of G431-mutated viruses Figure 4
Replication of G431-mutated viruses. SupT1 cells were transfected with the T20-dependent (GIA-SKY, top panel) and the 
wild-type (GIV-SNY, lower panel) with variation at position 431 as indicated. Replication was measured both in the presence 
(100 ng/ml) and absence of T20. Virus replication curves were made over a 12-day period. Syncytia formation at day 12 was 
recorded (-, no syncytia; ++++, all cells involved in syncytia). Position 431 variation in the GIA-SKY T20-dependent virus (top) 
and the wild-type GIV-SNY virus (bottom): wild-type 431G (closed circles), G431R (open circles), G431E (dashes) and G431A 
(open triangles, in wild-type only).Retrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
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[39]. The revertant, which produces significantly more
CA-p24 compared to the wild-type (see discussion), was
less sensitive (more resistant) to sCD4 than the wild-type,
indicating that it has reduced CD4 binding affinity. At the
highest sCD4 concentration (10 µg/ml), wild-type was
inhibited to 23%, whereas the revertant remained at 80%
replication capacity. At an intermediate 1 µg/ml sCD4
concentration, wild-type was inhibited to 60% however;
this concentration had no inhibitory effect on the rever-
tant.
We further wanted to analyse the gp41 structure of GIA-
SKY-G431R revertant and see if this virus is more sensitive
to HR1 inhibitors, which would suggest that gp41 is in an
"open" or "loose" conformation. For this, we used a gp41
antibody that binds to an open HR1 pre-fusion interme-
diate. This D5-IgG1 antibody specifically targets the gp41
HR1 region and can bind to a region slightly upstream of
the GIA motif [40]. Because the revertant contains the GIA
T20-resistant mutation, using T20 is not an option as this
revertant is resistant to the peptide (Fig. 2). The revertant
was considerably more sensitive (less resistant) to the D5-
IgG1 antibody than the wild-type. At the lowest concen-
tration (5 µg/ml), wild-type was unaffected, whereas the
revertant was inhibited to 45% replication capacity. At an
intermediate 50 µg/ml D5-IgG1 concentration, the rever-
tant was significantly inhibited to 17% replication capac-
ity, whereas the wild-type was inhibited to 78%. This
result suggests that the HR1 domain is exposed and more
susceptible to the inhibitor in the revertant Env protein.
The combined results of the reduced sensitivity to sCD4
and increased sensitivity to D5-IgG1 suggest that the
G431R mutation partially restores gp41 function of the
Env protein by modulating the Env-CD4 interaction and
6-helix bundle formation.
Conclusion
In this study, we performed forced evolution experiments
with a T20-dependent virus [20] in the absence of T20
with the aim to identify second site compensatory
changes, which could provide new mechanistic insights
into Env function and the T20-dependence mechanism.
Escape variants with improved viral replication were
selected in 5 independent evolution cultures. We
sequenced the complete HIV-1 Env gene and observed
several mutations. Strikingly, 3 evolution cultures con-
tained identical escape variants with the same glycine-to-
arginine substitution at position 431 of Env (all identical
codon changes GGA-to-AGA). Glycine 431 is located in
the CD4 binding region of Env gp120 and is highly con-
served among natural HIV-1 isolates, suggesting it plays a
key role in CD4 receptor engagement [32-35]. In order to
directly test the effect of the G431R mutation, we intro-
duced it back into the original GIA-SKY T20-dependent
molecular clone. Replication assays in SupT1 cells con-
firmed that the G431R mutation is sufficient to restore
replication in the absence of T20.
One may anticipate that phenotypic reversion of the T20-
dependent GIA-SKY virus would occur via back-mutation
of the SKY mutation in HR2 to either SNY or NNY to
remove the T20-dependence phenotype. This would pro-
duce the GIA single mutant, which is T20-resistant, but
not T20-dependent [20]. However, the GIA mutant has
diminished replication kinetics, which would place this
escape variant at a disadvantage to other escape variants
[20,28]. In addition, this evolution route requires a rela-
tively difficult transversion type of mutation (G-to-T),
whereas the G431R mutation is made by a simple transi-
tion type mutation (G-to-A) [41-43]. Back-mutation of
the GIA sequence to GIV is also not an option as the SKY
single mutant is a dead virus [20]. This implies that the
G431R substitution is selected as an alternative solution
to the conformational gp41 defect of the GIA-SKY mutant,
which is normally controlled by T20.
We previously reported that T20 is able to control or pre-
serve an early pre-fusion conformation of gp41 so that,
after CD4 and co-receptor engagement, gp41 conforma-
tional changes can occur and virus/cell fusion and entry
Cell-cell fusion assay with the G431-mutated Env variants Figure 5
Cell-cell fusion assay with the G431-mutated Env var-
iants. Assay of wild-type (GIV-SNY) and T20-dependent 
(GIA-SKY) viruses with position 431 variation as indicated, in 
the presence (20 ng/ml) and absence of T20. SupT1 cells 
were transfected with the mutants indicated below the X-
axis. One day later, transfected cells were mixed with SupT1 
cells containing a Tat-responsive LTR-luciferase reporter 
gene construct with (20 ng/ml) or without T20. After 24 
hours, formation of syncytia was analysed by light micros-
copy (-, no syncytia; ++++, all cells involved in syncytia) and 
quantitated by measurement of luciferase activity in cell 
extracts.Retrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
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can subsequently take place [20]. The G431R mutation
could similarly restore gp41 function by preventing the
abortive premature switch in gp41. We indeed measured
significantly reduced sensitivity to the sCD4 inhibitor
(Fig. 6, left panel). Because the C4 region has been impli-
cated as a contact site for CD4 receptor on the host cell
surface, these changes may affect the ability of Env to
interact with CD4 [32-35]. The X-ray structure of the HIV-
1 Env protein is consistent with this possibility because
amino acid 431 is located within the critical CD4 binding
domain [37,38]. Alternatively, the amino acid 431 change
may affect the Env-CD4 interaction in a more indirect
manner through an effect on the folding of this complex
glycoprotein. To test this, we used a gp41 antibody (D5-
IgG1) which targets the HR1 region of the pre-fusion gp41
conformation. For this antibody to have a more potent
inhibitory activity, the HR1 region of gp41 would need to
be more accessible and hence be in an "open" state, free
from bound HR2 [40]. We indeed measured increased
sensitivity to the D5-IgG1 antibody (Fig. 6, right panel).
The combined results of the reduced sensitivity to sCD4
and increased sensitivity to D5-IgG1 suggest that the
G431R mutation partially restores gp41 function of this
Env protein by modifying the Env-CD4 interaction and
gp41 conformational changes, thus preventing or modu-
lating the premature switch to the 6-helix bundle similar
to the effect of the T20 peptide on this mutant.
Interestingly, the G431R mutation has previously been
selected in long-term cultures of a translationally
impaired HIV-1 mutant [44,45]. Consistent with our cur-
rent results, reduced syncytia formation and increase CA-
p24 production compared to the wild-type virus was also
scored. This phenotype allows the infected SupT1 cells to
survive longer, thus producing more viral progeny. This
loss of fusogenicity via Env-CD4 interaction was meas-
ured via a cell-cell fusion assay and provides an obvious
advantage in the context of our T20-dependent GIA-SKY
mutant which is overly aggressive at engaging target cells,
resulting in premature syncytia formation [20]. Beddows
et al. [17] recently reported a similar finding where a C4
mutant Env showed increased sensitivity to Env antibod-
ies, reduced infectivity and adaptation to SupT1 cells.
In 1987, Kowalski et al. [46] demonstrated that inser-
tional mutations in gp41 HR2 region disrupt the gp120-
gp41 interaction and suggested that the HR2 region is a
"touch point" for gp41-gp120 interactions. More recently,
a strong link between the C4 region of gp120 and the
gp41-HR2 region (including the T20 sequence) has been
proposed by a number of research groups [16-18,46].
Short peptides designed to mimic the C4 region in gp120
have the ability to suppress the T20 inhibitory effect either
by preventing T20 from binding to the C4 region in gp120
and/or by modulating gp41 conformational changes via
Sensitivity of wild-type GIV-SNY and GIA-SKY-G431R revertant viruses to sCD4 and D5-IgG1 gp41 antibody Figure 6
Sensitivity of wild-type GIV-SNY and GIA-SKY-G431R revertant viruses to sCD4 and D5-IgG1 gp41 antibody. 
Bars represent CA-p24 values at day 6 post-transfection, which represent the relative differences in replication capacity in the 
presence of the sCD4 inhibitor and the D5-IgG1 antibody for the wild-type virus compared to the revertant virus. This is a 
representative experiment, similar results were observed in 2 independent experiments.Retrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
Page 9 of 11
(page number not for citation purposes)
interaction with the HR2 region in gp41. Alam et al. [16]
found an HR2/T20 peptide-binding site on soluble HIV-1
recombinant gp120. Furthermore, they demonstrated that
binding of T20 was induced by sCD4 and anti-gp120
human mAb A32 and was inhibited by the HIV-1 co-
receptor-binding site mAb 17b and C4 peptides. Their
results strongly suggest a link between the C4 region in
gp120 and the gp41-HR2 region. They suggested that a
stabilized HR2/Env conjugate may be a possible HIV-1
vaccine candidate with the potential for inducing antibod-
ies against transiently exposed epitopes on HIV-1 Env. It
would be interesting to investigate if our GIA-SKY-G431R
revertant, which has reduced sensitivity to sCD4 and
increased sensitivity to HR1 antibodies, may be such a
possible vaccine candidate.
We previously incorporated the T20-dependent pheno-
type in the doxycycline (dox)-dependent HIV-rtTA virus
that was described as a conditional live vaccine strain
[47,48]. Our current results indicate that the T20-control
may be lost by a single mutation in the Env gene (i.e.
G341R). However, we forced this evolutionary escape
route by culturing the virus without T20. Furthermore, the
dox-control will be used such that the virus is replicating
only transiently to induce the immune system and this
will restrict evolution and thus avoid unwanted evolu-
tionary paths.
Materials and methods
Cell transfection and CA-p24 determination
The SupT1 T-cell line was maintained in RPMI 1640 sup-
plemented with 10% fetal calf serum (FCS), penicillin and
streptomycin (both at 100 units/ml) and incubated at
37°C with 5% CO2. SupT1 cells were transfected with
HIV-1 molecular clones by means of electroporation.
Briefly, 5 × 106 cells were washed in RPMI 1640 contain-
ing 20% FCS, mixed with 0.5–5 µg of DNA in 0.4-cm
cuvettes, and electroporated at 250 V and 975 µF, fol-
lowed by resuspension of cells in RPMI 1640 with 10%
FCS. The transfected cells were split 24 hours post-trans-
fection and incubated with or without inhibitor or anti-
body. CA-p24 production was determined from culture
supernatant taken at various days post-transfection using
a CA-p24 antigen capture enzyme-linked immunosorbant
assay as previously described [49].
Virus evolution in cell culture
For the selection of revertant viruses, SupT1 cells were
transfected with 1 µg DNA of the GIA-SKY molecular
clone [20]. Transfected cells were split at approximately
16 hours post transfection into 6 separate culture flasks
and 0.5 × 106 fresh SupT1 cells were added in order to start
the 6 independent evolution cultures. We initially split
100 µl of cells plus supernatant when required onto unin-
fected SupT1 cells. When HIV-induced cytopathic effects
and increased CA-p24 production were apparent, virus
replication was maintained by passage of cell-free culture
supernatant onto uninfected SupT1 cells. Initially, we
used 100 µl cell-free culture supernatant to infect 5 ml
fresh SupT1 cells (approximately 0.5 × 106 cells), but we
gradually used less culture supernatant per passage. Cells
and supernatant samples were taken at regular time points
and stored at -70°C.
Proviral DNA isolation, PCR amplification and sequencing
HIV-1 infected cells (1 ml culture) were pelleted by cen-
trifugation at 4000 rpm for 4 min and the supernatant was
analysed for CA-p24 contents and stored at -70°C. The
cell pellet was lysed in 10 mM Tris-HCl (pH 8.0), 1 mM
EDTA, 0.5% Tween 20 and incubated with 500 µg Protei-
nase K/ml at 56°C for 60 min and heat-inactivated at
95°C for 10 min. Proviral DNA sequences of the entire
Env gene were PCR-amplified from solubilized cellular
DNA (5 µl) using the Expand High Fidelity PCR System
(Roche). Briefly, after incubation for 5 min at 94°C, the
reaction mixture was subjected to 35 PCR cycles in a type
9700 DNA thermal cycler (Perkin Elmer Cetus), with each
cycle including a denaturation step for 30 sec at 94°C, an
annealing step for 30 sec at 60°C and an extension step
for 3 min at 68°C. This was followed by a final extension
step of 7 min at 68°C. The PCR was performed with 50 ng
sense and antisense primers (WS1, 5'-ATAAGCTTAGCA-
GAAGACA-3', and 3'envMD4, 5'-GCAAAATCCTTTC-
CAAGCCC-3') in a 50 µl PCR reaction. DNA products
were analysed on a 1% agarose gel that was pre-stained
with ethidium bromide. PCR products were sequenced
directly using the DNA Big Dye Terminator Sequencing
Kit (ABI, Foster City, California) and an ABI 377 auto-
mated sequencer.
Construction of LAI molecular clones
The full-length molecular HIV-1 clone pLAI was used to
produce wild-type and mutant viruses [50]. We already
described the wild-type variant with the GIV-SNY
sequence as observed in the patient isolate in place of the
GIV-NNY sequence that is present in the LAI molecular
clone [20]. The plasmid pRS1, designed to subclone
mutant Env genes, was generated as previously described
[51]. Mutations were introduced in pRS1 using the Quick-
change mutagenesis kit (Stratagene, La Jolla, CA, USA)
and the entire Env gene was verified by DNA sequencing.
Mutant Env genes in pRS1 were cloned back into pLAI as
SalI-BamHI fragments. These included the G431R, G431E
and G431A mutations in the C4 region in combination
with the gp41 wild-type GIV-SNY or mutant GIA-SKY.
Cell-cell fusion assay
SupT1 cells (5 × 106) were transfected with 5 µg of the
indicated pLAI variants and/or the pcDNA3-Tat expres-
sion plasmid as described above. The cells were culturedRetrovirology 2006, 3:84 http://www.retrovirology.com/content/3/1/84
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for approximately 18 hours, spun at 1200 rpm for 10 min
and resuspended in fresh media containing saquinavir (1
µM final concentration), with (20 ng/ml) or without T20.
Cells were subsequently mixed with SupT1 cells that were
transfected the previous day with 5 µg LTR-luciferase
reporter plasmid. Cells were cultured for 24 hours, scored
for syncytia formation and the cell lysate was assayed for
luciferase production (Promega, Madison, WI, USA),
which was measured with a luminometer. The output was
expressed as relative light units (RLU).
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